Ascendis Pharma (ASND) PT Raised to $200 at Goldman Sachs

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. AVGO
2. CDNS
3. SPY
4. META
5. JBLU
6. ANT
7. SSD
8. ARTV
9. AAPL
10. INTC

Go back to Ascendis Pharma (ASND) PT Raised to $200 at Goldman Sachs

Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo

September 16, 2024 7:00 AM EDT

    TransCon CNP demonstrated AGV superior to placebo with LS mean treatment difference of 1.49 cm/year at Week 52 (p... More

Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024

September 13, 2024 8:30 AM EDT


Anti-tumor clinical responses were observed in 29% (4/14) of efficacy-evaluable patients with PROC treated with TransCon IL-2 / in combination with chemotherapy Initial data suggest clinical activity in heavily pre-treated PROC patients and that TransCon IL-2 / in combination with chemotherapy was generally well-tolerated

COPENHAGEN, Denmark, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced initial data showing signs of clinical activity in heavily pre-treated patients... More